REQUEST # 4349252

Novel Drug Candidates for Obstetric and Gynecological Diseases

RESPONSE DUE DATE: September 21, 2017

Opportunity
Joint development, licensing

Timeline
To be discussed, depending on the development stage of the candidate

Financials
Details to be negotiated, depending on the contents of the proposal.

REQUEST FOR PROPOSAL DESCRIPTION

NineSigma, representing a pharmaceutical company with special focus on obstetric and gynecological area, seeks novel drug candidates for the treatment of obstetric and gynecological diseases.

The client, with high level of expertise in drug discovery research and clinical development in this area, has been aiming at expanding their product portfolio and pipeline.

The obstetric and gynecological diseases are medical conditions with high unmet medical needs, therefore, development of novel drugs are highly anticipated. The client strives for early launch of a new drug in order to provide new treatment options to patients.

The client has thus issued this open request in order to collaborate with external organizations that possesses promising drug candidate.

Target diseases
This open request targets obstetric and gynecological diseases except for cancer. Target diseases include, but are not limited to, the following, but other drugs for the treatment of obstetric and gynecological disease are also anticipated:
- Endometriosis
- Adenomyosis uteri
- Uterine myoma
- Polycystic ovarian syndrome

Requirements for drug candidates
The client seeks drug candidates that meet the following requirements:

- Modality:
  - Low molecular weight compounds, antibodies, peptides, proteins, and diagnostic biomarkers
  - The mechanism of action should be different from existing drugs
    - However, candidates with a known mechanism that can be clearly differentiated from existing drugs are acceptable.
  - High efficacy and safety can be expected
    - For safety, it is required that data has been obtained from a non-clinical study or adverse events are considered very unlikely to occur from the point of mechanism.

- Development level:
  - The stage should be from pre-clinical study to Phase I trial
  - Optimization of the compound has been completed and the candidate can be presented
  - A GLP-Tox study need not necessarily have been conducted.
DRUG CANDIDATES NOT OF INTEREST

The following drug candidates are out of the scope:

- Candidates for cancer drugs
- The drug candidates in the phase II trial

ANTICIPATED PROJECT PHASES OR PROJECT PLAN

Respondents should submit proposals using the attached Response Template.

The client will review submitted proposals and possibly ask clarifying questions before selecting the most suitable candidates for collaboration. The client will select the best candidate(s) through evaluations. During the selection process, the client may execute non-disclosure agreements (NDA) with selected respondent(s), seek further information disclosure, and discuss specific development targets or potential opportunities. The client will execute necessary agreement(s) with the selected respondent(s) and move to the advanced development phase. Specifics of any collaboration will be determined through consultation with the concerned parties.

ITEMS TO BE INCLUDED IN THE PROPOSAL

Responses will use the Proposal Template which is linked to the “attachments” shown at the bottom of the link <REQ4349252> and include the following items:

- Target diseases
- Overview of the proposed candidate (modality, route of administration, mechanism of action, etc.)
- Examples (pharmacology, safety, toxicity, pharmacokinetics, etc.)
- Current research and development stage
- Future research plans
- Any requests concerning the collaboration
- Status of intellectual property related to the proposed technology
- Research achievements

SUBMITTING A RESPONSE

All proposals should be submitted online at <REQ4349252>, the NineSigma open innovation community, according to the instructions in the Proposal Template. Supplemental files may be submitted in addition to the proposal document.

For assistance, please contact the Solution Provider Help Desk (PhD2@ninesigma.com).

REQUEST GUIDELINES

Non-Confidential Disclosure

By submitting a response you represent that the response does not and will not be deemed to contain any confidential information of any kind whatsoever.

Response Evaluation

NineSigma’s client will evaluate the response using the following criteria:

- Overall scientific and technical merit of the proposed approach
- Approach to proof of concept or performance
- Potential for proprietary position (i.e., is the technology novel or protectable)
- Economic potential of concept
- Respondent’s capabilities and related experience
- Realism of the proposed plan and cost estimates

Response Selection

By submitting a response, you acknowledge that NineSigma’s client reserves the sole and absolute right and discretion to select for award all, some, or none of the responses received for this announcement. NineSigma’s client also may choose to select only specific tasks within a proposal for award. NineSigma’s client has the sole and absolute discretion to determine all award amounts. NineSigma will contact respondents with highly responsive proposals for next steps, or the client may contact respondents directly.